Expression of HMP/AN2, a melanoma associated antigen, in murine cerebral gliomas: potential for radioimmunotargeting

[1]  Jonathan Lerner,et al.  Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression , 2007, Journal of Neuro-Oncology.

[2]  Mark R Gilbert,et al.  Chemoradiotherapy in malignant glioma: standard of care and future directions. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. S. Lee,et al.  Performance Measurement of the microPET Focus 120 Scanner , 2007, Journal of Nuclear Medicine.

[4]  T. Merchant,et al.  Effects of fractionated radiation on the brain vasculature in a murine model: blood-brain barrier permeability, astrocyte proliferation, and ultrastructural changes. , 2006, International journal of radiation oncology, biology, physics.

[5]  M. Sajjad,et al.  Optimization of 124I production via 124Te(p,n)124I reaction. , 2006, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[6]  H. Hamada,et al.  Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy , 2006, Cancer science.

[7]  Giovanni Paganelli,et al.  Improved Tumor Targeting by Combined Use of Two Antitenascin Antibodies , 2005, Clinical Cancer Research.

[8]  M. Ciesielski,et al.  Immunotherapeutic strategies for malignant glioma. , 2004, Cancer control : journal of the Moffitt Cancer Center.

[9]  Luther W Brady,et al.  Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. , 2004, International journal of radiation oncology, biology, physics.

[10]  L. Liau,et al.  Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. , 2003, Cancer research.

[11]  Sanjiv S Gambhir,et al.  124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  Richard Reynolds,et al.  NG2-expressing glial progenitor cells: an abundant and widespread population of cycling cells in the adult rat CNS , 2003, Molecular and Cellular Neuroscience.

[13]  Glyn Johnson,et al.  Dynamic, contrast‐enhanced perfusion MRI in mouse gliomas: Correlation with histopathology , 2003, Magnetic resonance in medicine.

[14]  S. Al-Sarraj,et al.  The glial precursor proteoglycan, NG2, is expressed on tumour neovasculature by vascular pericytes in human malignant brain tumours , 2002, Neuropathology and applied neurobiology.

[15]  J. Trotter,et al.  AN2, the mouse homologue of NG2, is a surface antigen on glial precursor cells implicated in control of cell migration , 2002, Journal of neurocytology.

[16]  Olav Haraldseth,et al.  NG2 proteoglycan promotes angiogenesis‐dependent tumor growth in the central nervous system by sequestering angiostatin , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  P. Caliceti,et al.  Pretargeted adjuvant radioimmunotherapy with Yttrium-90-biotin in malignant glioma patients: A pilot study , 2002, British Journal of Cancer.

[18]  S. U. Kim,et al.  MAGE-E1, a new member of the melanoma-associated antigen gene family and its expression in human glioma. , 2001, Cancer research.

[19]  Y. Shoshan,et al.  Expression of oligodendrocyte progenitor cell antigens by gliomas: implications for the histogenesis of brain tumors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[20]  M. Chekenya,et al.  The NG2 chondoitin sulfate proteoglycan: role in malignant progression of human brain tumours , 1999, International Journal of Developmental Neuroscience.

[21]  D L Morton,et al.  Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. , 1997, The American journal of pathology.

[22]  P. Itin,et al.  Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[23]  R. McLendon,et al.  Tumor antigens in astrocytic gliomas , 1995, Glia.

[24]  M. Schrappe,et al.  Long-term growth suppression of human glioma xenografts by chemoimmunoconjugates of 4-desacetylvinblastine-3-carboxyhydrazide and monoclonal antibody 9.2.27. , 1992, Cancer research.

[25]  S. Ferrone,et al.  Binding parameters and idiotypic profile of the whole immunoglobulin and Fab' fragments of murine monoclonal antibody to distinct determinants of the human high molecular weight-melanoma associated antigen. , 1992, Cancer research.

[26]  L. Zardi,et al.  Treatment of intracranial human glioblastoma by direct intratumoral administration of 131I‐labelled anti‐tenascin monoclonal antibody BC‐2 , 1992, International journal of cancer.

[27]  M. Schrappe,et al.  Correlation of chondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial cells with the malignant phenotype of astroglial cells. , 1991, Cancer research.

[28]  J. Prince,et al.  The primary structure of NG2, a novel membrane-spanning proteoglycan , 1991, The Journal of cell biology.

[29]  M. Zalutsky,et al.  Radioiodination of antibodies via N-succinimidyl 2,4-dimethoxy-3-(trialkylstannyl)benzoates. , 1990, Bioconjugate chemistry.

[30]  D. Bigner,et al.  Radioimmunotherapy of intracerebral human glioma xenografts with 131I-labeled F(ab')2 fragments of monoclonal antibody Mel-14. , 1990, Cancer research.

[31]  S. Ferrone,et al.  Characterization of syngeneic antiidiotypic monoclonal antibodies to murine anti-human high molecular weight melanoma-associated antigen monoclonal antibodies. , 1989, Journal of immunology.

[32]  S. Ferrone,et al.  Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: comparison with other methods of purification. , 1989, Hybridoma.

[33]  W. Stallcup,et al.  Bipotential glial precursor cells of the optic nerve express the NG2 proteoglycan , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[34]  S. Ferrone,et al.  Syngeneic antiidiotypic antisera to murine antihuman high-molecular-weight melanoma-associated antigen monoclonal antibodies. , 1987, Cancer research.

[35]  G. Mariani,et al.  Multicenter study of immunoscintigraphy with radiolabeled monoclonal antibodies in patients with melanoma. , 1986, Cancer research.

[36]  P. Bunn,et al.  Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. , 1984, Journal of immunological methods.

[37]  A. Neville,et al.  Monoclonal antibodies to detect human tumours: an experimental approach. , 1981, Journal of clinical pathology.

[38]  H. Immervoll,et al.  NG2/HMP proteoglycan as a cancer therapeutic target. , 2007, Methods in molecular biology.

[39]  R. Coleman,et al.  Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  S. Ferrone,et al.  Regression of human melanoma xenografts in nude mice injected with methotrexate linked to monoclonal antibody 225.28 to human high molecular weight-melanoma associated antigen , 2005, Cancer Immunology, Immunotherapy.

[41]  S. Ferrone,et al.  Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. , 2004, Critical reviews in immunology.

[42]  H. Hirschberg,et al.  Immunotoxin treatment targeted to the high-molecular-weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme. , 2004, Journal of neurosurgery.

[43]  D. Bigner,et al.  Fibronectin and glial fibrillary acidic protein expression in normal human brain and anaplastic human gliomas. , 1982, Cancer research.